Publication
[Molecular Diagnostics and Personalized Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)].
Marie Semmler, Jozefina Casuscelli, Stefanie Zschäbitz, Johann-Christoph Jann
Aktuelle UrologieSep 16, 2026PMID 42748971doi:10.1055/a-2927-6325 English AbstractJournal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260918-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Metastatic castration-resistant prostate cancer (mCRPC) is a biologically heterogeneous tumor disease. Alterations in homologous recombination repair (HRR) genes, defects in the mismatch repair (MMR) system, alterations in the classical tumor suppressor genes TP53, RB1, and PTEN, and androgen…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.